What are the drugs having potential against COVID-19?

Kaan Kucukoglu1 · Nagihan Faydalı1 · Dilek Bul1

Received: 22 May 2020 / Accepted: 28 August 2020 / Published online: 10 September 2020
© Springer Science+Business Media, LLC, part of Springer Nature 2020

Abstract
A disease emerged in the city of Wuhan, Hubei Province, Central China in the last month of 2019. It was pneumonia caused by a newly emerged coronavirus called COVID-19, later. Coronaviruses are enveloped RNA viruses belong to the Betacoronavirus family and infected birds, humans, and other mammals. In March 2020, the World Health Organization declared the COVID-19 outbreak could be characterized as a global pandemic because the disease spread, and a large number of people were infected and died in many countries on different continents by virtue of this new virus. Now, intensive work is underway about the pathogenic mechanisms and epidemiological properties of COVID-19, and a great effort is made to develop effective specific therapeutic drugs, vaccines, and/or treatment strategies against these diseases. Herein, we have focused on all treatment options available against COVID-19 pneumonia in this text.

Keywords COVID-19 · Pandemic · Drug · Immunotherapy · Cellular therapy · Antiviral

Introduction
Coronaviruses (CoVs) belong to the subfamily Orthocoronavirinae in the family of Coronaviridae. In this family, there are four types of viruses: α-coronavirus, β-coronavirus, γ-coronavirus, δ-coronavirus (Banerjee et al. 2019; Yang and Leibowitz 2015). The CoV genome is an enveloped, positive-sense, and single-stranded RNA whose size is 26–32 kb and it has the largest genome of known RNA viruses. It is known that α- and β-CoV types cause infections in mammals as δ- and γ-CoVs infect birds (Banerjee et al. 2019; Yang and Leibowitz 2015; Schoeman and Fielding 2019). Severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) belonging to β-CoVs are the most well-known aggressive strains of coronaviruses and cause viral pneumonia outbreaks, recently. SARS first appeared in China in 2002, spread and resulted in 8437 cases and 813 deaths with an 11% mortality rate according to the World Health Organization (WHO) reports (Song et al. 2019; Graham et al. 2013; Zhong et al. 2003). MERS, which emerged in Saudi Arabia in 2012 firstly, caused 2206 patients in 27 countries, 1831 cases in Saudi Arabia with 787 deaths with the mortality rate of 37% between June 2012 and April 2018 (Zumla et al. 2015; Hui et al. 2018; Su et al. 2015; Nassar et al. 2018).

In December 2019, some people had sickness with unknown etiology in Wuhan City where 11 million residents live, Hubei Province in China. This sickness was a kind of pneumonia and the sequence analysis revealed that the cause of it was a novel CoV whose genome structure was more than 82% identical to those of SARS-CoV, following this phenomenon was named as coronavirus disease 2019 (COVID-19) (Xu et al. 2020; Wong et al. 2020; Li et al. 2020; Zhang et al. 2020; Chan et al. 2020). Unfortunately, case numbers are increasing continuously day by day, the COVID-19 disease has spread primarily to China, the Islamic Republic of Iran, and Europe. It was determined that the COVID-19 disease had human-to-human transmission ability by the National Health Commission of China on 20 January 2020. COVID-19 outbreak a public health emergency of international concern (PHEIC) on 30 January 2020.

Beginning in March 2020, COVID-19 has spread in 72 countries quickly, caused over 90,000 confirmed cases and 2946 deaths (Li et al. 2020). As this outbreak turned into a global threat, the WHO announced that the COVID-19 outbreak could be characterized as a global pandemic, on 12 March 2020 (The World Health Organization Regional
Office for Europe. Coronavirus disease (COVID-19) outbreak news). 22,256,220 cases and 782,456 deaths caused by the COVID-19 pandemic according to the WHO records on 21 August 2020 (The World Health Organization Home. Coronavirus disease 2019 current case numbers).

Currently, the man has no registered specific vaccines or therapy methods for COVID-19 accepted by the whole world. WHO stated that there were nine vaccine candidates against COVID-19 in the advanced stages of clinical trials (timesnownews.com). Russia government announced the world’s first COVID-19 vaccine called as Sputnik V (Table 1) was developed by the Gamaleya Research Institute of Epidemiology and Microbiology on 12 August (science-mag.org/news), but WHO declared that there is not enough information about Sputnik V and they are in contact with Russia (timesnownews.com). That’s why, there is an urgent need to find drugs or vaccines which can be used in the treatment of COVID-19 infections, effectively. Nevertheless, there are some reports and data from studies related to the use of known drugs like chloroquine and remdesivir that have proved efficacy on COVID-19 pneumonia both in vitro and in animal models. In this context, we summarize therapeutic options available for the treatment of COVID-19.

**Therapy**

The pharmaceutical interventions available for COVID-19 therapy can be divided into several groups: immunotherapy, cellular therapy, antiviral and other drugs, and Chinese medicine.

**Immunotherapy**

**Immunoglobulins**

Immunoglobulins are used to treat for various diseases, for example, Guillain–Barre Syndrome, Kawasaki disease as well as some pathologic conditions such as idiopathic thrombocytopenia purpura and chronic inflammatory demyelinating polyneuropathy (Cherin et al. 2016). Various glycoproteins on virus surfaces or the protein shell of a non-enveloped virus could be recognized by extensively neutralizing antibodies, but HIV-1 (human immunodeficiency virus), dengue virus, hepatitis C, Ebola virus, and influenza viruses can mutate superficial glycoproteins, thus they avoid the antibody response. This condition creates an obstacle to develop new therapies for such infections (Srinivasan et al. 2016). Although intravenous gammaglobulin has adverse reactions, it is probably the safest immunomodulating drug. Intravenous gammaglobulin has been used extensively for patients with SARS in Singapore, but venous thromboembolism including pulmonary embolism has emerged in one-third of critically ill patients (Lew et al. 2003). Human immunoglobulin is testing in pneumonia patients with COVID-19 and there are 478 clinical trials concerning immunoglobulins, of them 18 trials were finished (NIH US National Library of Medicine clinical trial database, https://www.clinicaltrials.gov/ct2/results?cond=Covid19&term=immunoglobulin&type= &rslt=&age_v=&gnr=&intr=&titles=&outc=&spons=& &lead=&id=&cntry=&state=&city=&dist=&lcn=& &rsrh=&&strd_s=&&strd_e=&&pred_s=&&pred_e=&&sfpd_s=& &sfpd_e=&&rfpd_s=&&rfpd_e=&&lupd_s=&&lupd_e=&&sort=).

**Interferons**

Interferons (IFNs) are substances having protein structure that bind to receptors on cellular surfaces and initiate JAK-STAT signaling cascades (Schneider et al. 2014). IFNs are considered as two types: Type I and Type II IFNs. Type I IFNs, which make up of two different proteins: IFN-α and IFN-β are inclusive of natural immunity against viral infections. Type I IFN release forms are the first line of defense against infections caused by viruses. In the 7th published National Health Council (NHC) guideline, IFN-α single or in combination with other drugs are indicated in the clinical usages (Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th edition)). IFN-α included in Type I IFNs is grown very rapidly as part of the congenital immune response to infections caused by viruses and inhibits the transcription of animal and human coronaviruses (Mathias et al. 2010; ClinicalTrials.gov [Internet] 2020a). In addition, they support innate and adaptive immune responses against viral infections. IFN-α effectively inhibited SARS-CoV replication in vitro experiments (Ströher et al. 2004; Zorzitto et al. 2006). It was shown that Type I interferons with the inclusion of IFN-β could inhibit the replication of SARS-CoV in vitro, too (Morgenstern et al. 2005). It was revealed that SARS-CoV blocked IFN transcription in infected cells and these cells might partly repair their congenital immune responsiveness to SARS-CoV following small amounts of IFNs had been prepared (Kuri et al. 2009). It has been shown that cynomolgus monkeys are preserved from SARS-CoV infection via IFN-α therapy, too (Haagmans et al. 2004). In a pilot clinical trial, synthetic recombinant IFN-α was proved to be active against SARS (Loutfy et al. 2003). Additionally, IFN-α-2a and ribavirin combination prolonged the survival of people with severe MERS-CoV infection (Mustafa et al. 2018). The different controlled test has been launched to test the efficiency of lopinavir/ritonavir and IFN-α-2b in hospitalized people with SARS-CoV-2 infections (ChiCTR2000029308) (Martinez 2020).
| Vaccine candidate | Modality | Sponsor | Study identifier/status | Study location |
|-------------------|----------|---------|-------------------------|----------------|
| **BCG** (Bacillus Calmette-Guérin) **Live attenuated vaccines** | UMC Utrecht | NCT04328441/Phase 3 | Netherlands |
| | Ain Shams University | NCT04350931/Phase 3 | Egypt |
| | Universidad de Antioquia | NCT04362124/Phase 3 | Colombia |
| | Tuberculosis Research Centre, India | NCT04475302/Phase 3 | India |
| | Radboud University | NCT04417335/Phase 4 | Netherlands |
| | TASK Applied Science | NCT04379336/Phase 3 | South Africa |
| | Hospital Universitario Dr. Jose E. Gonzalez | NCT04461379/Phase 3 | Mexico |
| | Hellenic Institute for the Study of Sepsis | NCT04414267/Phase 4 | Greece |
| | Murdoch Childrens Research Institute | NCT04327206/Phase 3 | Australia |
| | University of Campinas, Brazil | NCT04369794/Phase 4 | Brazil |
| | Bandim Health Project | NCT04373291/Phase 3 | Denmark |
| | Texas A&M University | NCT04348370/Phase 4 | United States |
| | Assiut University | NCT04347876/Unspecified | Egypt |
| | Direction des Soins de Santé de Base | NCT04384614/Unspecified | Tunisia |
| | Assistance Publique - Hôpitaux de Paris | NCT04384549/Phase 3 | France |
| **MMR vaccine** | Louisiana State University Health Sciences Center in New Orleans | NCT04475081/Phase 3 | United States |
| **Oral polio vaccine** | Bandim Health Project | NCT04445428/Phase 4 | Guinea-Bissau |
| **VPM1002** | University Health Network, Toronto | NCT0439045/Phase 3 | Canada |
| | Vakzine Projekt Management GmbH | NCT04387409/Phase 3 | Germany |
| | Vakzine Projekt Management GmbH | NCT0435379/Phase 3 | Germany |
| **RUTI** | Fundació Institut Germans Trias i Pujol | NCT04453488/Phase 3 | Germany |
| **CoronaVac (PiCoVacc)** | Sinovac Research and Development Co., Ltd. | NCT04383574/Phase 1 | China |
| **mRNA-1273** | National Institute of Allergy and Infectious Diseases (NIAID) | NCT04283461/Phase 1 | United States |
| | ModernaTX, Inc. | NCT04405076/Phase 2 | United States |
| | ModernaTX, Inc. | NCT04470427/Phase 3 | United States |
| **AZD1222 (ChAdOx1 nCoV-19)** | AstraZeneca | NCT04516746/Phase 3 | United States |
| **BNT162** | BioNTech SE | NCT04368728/Phase 2 | United States |
| | BioNTech RNA Pharmaceuticals GmbH | NCT04380701/Phase 1 | Germany |
| **Ad5-nCoV** | CanSino Biologics Inc. | NCT04398147/Phase 1 | Canada |
| Vaccine candidate     | Modality            | Sponsor                                                                 | Study identifier/status                     | Study location     |
|-----------------------|---------------------|-------------------------------------------------------------------------|---------------------------------------------|--------------------|
| AG0301-COVID-19       | DNA vaccine         | AnGes, Inc.                                                             | NCT04463472/Phase 1                         | Japan              |
|                       |                     |                                                                        | NCT04505722/Phase 3                         | Japan              |
|                       |                     |                                                                        | NCT04509947/Phase 1                         | United States      |
|                       |                     |                                                                        | NCT04386252/Phase 1                         | United States      |
| Ad26.COV2.S           | Viral vector        | Janssen Vaccines & Prevention B.V.                                     |                                            |                    |
|                       |                     |                                                                        |                                            |                    |
| AV-COVID-19           | Cellular vaccine    | Aivita Biomedical, Inc.                                                |                                            |                    |
|                       |                     |                                                                        |                                            |                    |
| Covaxin (BBV152)      | Inactivated virus   | Bharat Biotech International Limited                                   | NCT04471519/Phase 1                         | India              |
|                       |                     |                                                                        |                                            |                    |
| Sputnik V (Gam-COVID-Vac) | Viral vector        | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | NCT0436471/Phase 1                         | Russian Federation |
|                       |                     |                                                                        |                                            |                    |
|                       |                     | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | NCT0437875/Phase 1                         | Russian Federation |
|                       |                     |                                                                        |                                            |                    |
| GX-19                 | DNA vaccine         | Genexine, Inc.                                                          | NCT04445389/Phase 1                         | South Korea        |
|                       |                     |                                                                        |                                            |                    |
| INO-4800              | DNA vaccine         | International Vaccine Institute                                         | NCT04447781/Phase 1                         | South Korea        |
|                       |                     |                                                                        |                                            |                    |
| KBP-COVID-19          | Protein-based       | Inovio Pharmaceuticals                                                  | NCT04336410/Phase 1                         | United States      |
|                       |                     |                                                                        |                                            |                    |
|                       |                     | Kentucky BioProcessing, Inc.                                           | NCT04473690/Phase 1                         |                    |
|                       |                     |                                                                        |                                            |                    |
| LUNAR-COV19 (ARCT-021) | RNA vaccine         | Arcturus Therapeutics, Inc.                                            | NCT0480957/Phase 1                          | Singapore          |
|                       |                     |                                                                        |                                            |                    |
| V-SARS                | Inactivated virus   | Immunitor LLC                                                           | NCT04380532/Phase 1                         | Canada Mongolia    |
|                       |                     |                                                                        |                                            |                    |
| Bac-TRL-Spike         | DNA vaccine         | Symvivo Corporation                                                     | NCT04334980/Phase 1                         | United States      |
|                       |                     |                                                                        |                                            |                    |
|                       |                     | GeneCure Biotechnologies                                                | NCT04428073/Phase 1                         | United States      |
|                       | Protein-based       |                                                                        |                                            |                    |
|                       |                     |                                                                        |                                            |                    |
|                       | RNA vaccine         | CureVac AG                                                              | NCT04515147/Phase 2                         | Belgium Germany    |
|                       |                     |                                                                        |                                            |                    |
|                       |                     | CureVac AG                                                              | NCT04494276/Phase 1                         |                    |
|                       |                     |                                                                        |                                            |                    |
| MVC-COV1901           | Protein-based       | Medigen Vaccine Biologics Corp.                                         | NCT04487210/Phase 1                         | Taiwan             |
|                       |                     |                                                                        |                                            |                    |
|                       |                     | The University of Queensland                                            | NCT04495933/Phase 1                         | Australia          |
|                       | Protein-based       |                                                                        |                                            |                    |
|                       |                     |                                                                        |                                            |                    |
| SCB-2019 (COVID-19 S-Trimer) | Protein-based      | Clover Biopharmaceuticals AUS Pty Ltd                                  | NCT04405908/Phase 1                         | Australia          |
|                       |                     |                                                                        |                                            |                    |
| TMV-083               | Engineered live attenuated virus                                      | Institut Pasteur                                                        | NCT04497298/Phase 1                         | Belgium France     |
Several combinations of IFN-α or IFN-β with other antivirals for instance lopinavir/ritonavir and/or ribavirin have been studied for the treatment of patients with SARS. Nitazoxanide, a Type I IFN inducer used for parasitic infection in humans, has been tried as an antiviral agent due to the ability to inhibit the replication of several RNA and DNA viruses (Pillaiyar et al. 2020). As of now, there are 87 clinical trials are underway about IFNs against COVID-19, of them 6 clinical trials were completed (NIH US National Library of Medicine clinical trial database, https://clinicaltrials.gov/ct2/results?cond=Covid19&term=interferon&type=&srslt=&age_v=&&gnrdr=&&intr=&&titles=&&outc=&&spons=&&lead=&&id=&&cntry=&&state=&&city=&&dist=&&locn=&&sub=&&strd_s=&&strd_e=&&prcd_s=&&prcd_e=&&sfpd_s=&&sfpd_e=&&rfpd_s=&&rfpd_e=&&lupd_s=&&lupd_e=&&sort=). Recently, new clinical data for IFN-1-β has been obtained and it has been concluded that there is insufficient data to advise either for or against the use of IFN-1-β for the therapy of early (<7 days from symptom onset) mild and moderate COVID-19 pneumonia (NIH COVID-19 Treatment Guidelines, https://www.covid19treatmentguidelines.nih.gov/whats-new/).

**Convalescent plasma therapy**

Antiviral antibodies, namely, IgG, IgA, IgM, IgE, and IgD available in convalescent plasma can be obtained from recovered patients and they can be used to treat patients viral infections, effectively. So far, this method has been widely utilized in some infectious diseases, for instance, poliomyelitis, influenza A (H5N1), and Ebola (Zhou et al. 2007; van Griensven et al. 2016; Rinaldo 2005). In addition to this, passive immunization might be useful by making use of convalescent plasma from people with SARS-CoV infection. In Taiwan and Hong Kong convalescent plasma therapy has been tested on a small number of SARS-CoV-infected patients during the early course of the outbreak and this method has been determined to be useful (Cheng et al. 2005; Wong and Yuen 2008; Yeh et al. 2005). In view of these findings, convalescent plasma therapy can be a promising option for the therapy and prevention of COVID-19 pneumonia cases.

Convalescent plasma may be called as passive immunotherapy, too. If no specific vaccines or medications are available for arising infection-related diseases, this therapy method is generally applied (Marano et al. 2016). The feasibility, safety, and clinical efficacy of this therapy method has been tested in critically ill MERS patients and it has been revealed to have an immunotherapeutic potential (Arabi et al. 2015). Similarly, convalescent plasma gained from recovered SARS patients has been useful to treat other SARS patients (Cheng et al. 2005; Soo et al. 2004). One important thing to say is this, World Health Organization under Blood Regulators Network recommends the use of convalescent plasma or serum if there is no vaccination and antiviral medications for an arising virus. Convalescent plasma therapy should be normally used against COVID-19 on critically ill patients if it is available (Zhang and Liu 2020). Now, there are 140 clinical trials to appreciate the efficacy and safety of convalescent plasma for the therapy of COVID-19 and, of them nine trials were completed (NIH US National Library of Medicine clinical trial database, https://www.clinicaltrials.gov/ct2/results?cond=Covid19&term=convalescent+plasma&type=&srslt=&age_v=&&gnrdr=&&intr=&&titles=&&outc=&&spons=&&lead=&&id=&&cntry==&state=&&city=&&dist=&&locn=&&sub=&&strd_s=&&strd_e=&&prcd_s=&&prcd_e=&&sfpd_s=&&sfpd_e=&&rfpd_s=&&rfpd_e=&&lupd_s=&&lupd_e=&&sort=).

**Monoclonal antibody**

It was determined that one recombinant human monoclonal antibody (mAb) (single-chain variable region fragments, scFvs 80R) inhibited S1 domain of S protein of SARS-CoV (Sui et al. 2004). Depending on the development of monoclonal antibodies, the SARS-CoV-2 outbreak can be prevented. Several studies revealed that some monoclonal antibodies which aim to the SARS-CoV spike protein could prevent the virus entry into the host cells (ter Meulen et al. 2006; Traggiai et al. 2004). Neutralizing monoclonal antibodies target the 193-amino acid receptor-binding domain (RBD) of the spike protein to perform their functions (Wong et al. 2004). Depending on the development of monoclonal antibodies alone or in combination could be a promising therapeutic candidate for the therapy of COVID-19 pneumonia.

Patients with severe COVID-19 infection experienced a cytokine storm with increased plasma concentrations of interleukins IL-6, IL-2, IL-7, and IL-10 and tumor necrosis factor TNF-α. This syndrome is described by fever and multiorgan failure. IL-6, interferon-gamma (IFN-γ), TNF-α, and IL-10 are cytokines including in cytokine release pathogenesis (Wang and Han 2018). Especially, IL-6 acts as the central mediator of cytokine release syndrome (Lee et al. 2014).

For the therapy of COVID-19 pneumonia, immunomodulant therapy is not recommended routinely. Nevertheless, considering the clinical and laboratory findings consistent with cytokine release syndrome and considering the formation of pulmonary edema and hyaline membranes, a targeted therapy could be useful in selected patients with severe pneumonia in association with respiratory support during a short time (Lombardy Section Italian Society Infectious and Tropical Diseases 2020).

Currently, there are 47 clinical trials are being conducted for monoclonal antibodies in the therapy of COVID-19 and,
no study was being completed (NIH US National Library of Medicine clinical trial database, https://www.clinicaltrials.gov/ct2/results?cond=Covid19&term=monoclonal+antibody&type=&rslt=&age_v=&gnrdr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&lonc=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=).

**Tocilizumab**

Tocilizumab (Fig. 1) is a monoclonal antibody that aims to the IL-6 receptor. This agent can be used against COVID-19 in patients with severe and extensive lung disease with elevated IL-6 levels. Thus, the systemic inflammatory response syndrome by the viral-induced cytokine storm can be discontinued (Lombardy Section Italian Society Infectious and Tropical Diseases 2020). As on date, 65 clinical trials are being carried out to know the efficacy of tocilizumab in COVID-19 pneumonia, of them 4 trials were finished (NIH US National Library of Medicine clinical trial database, https://www.clinicaltrials.gov/ct2/results?cond=Covid19&term=tocilizumab&type=&rslt=&age_v=&gnrdr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&lonc=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=).

**Bevacizumab**

Bevacizumab (Fig. 2), a humanized monoclonal antibody, aims vascular endothelial growth factor (VEGF) (ClinicalTrials.gov [Internet] 2020b; Wang et al. 2004). It has the ability to decrease the VEGF levels produced by hypoxia, severe inflammation, and upregulation of the infected respiratory tract epithelium; these symptoms might restrain the edema in patients suffered from COVID-19 pneumonia (Wang et al. 2004). There are only three clinical trials are underway about bevacizumab, at present (NIH US National Library of Medicine clinical trial database, https://www.clinicaltrials.gov/ct2/results?cond=Covid19&term=bevacizumab&type=&rslt=&age_v=&gnrdr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&lonc=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=).

**Cyclosporine A**

Cyclosporine A (Fig. 3) which has been used in transplantation widely as well as in the therapy of autoimmune disorders is an immunosuppressive drug. Because cyclosporine A has been used extensively, the survival rates of patients and grafts improved highly following solid-organ transplantation (Ziaei et al. 2016). It was claimed that nucleocapsid protein (NP) of SARS-CoV had a substantial role in the process of virus particle accumulation and release. In addition, it could connect to human cyclophilin A which is a key member of immunophilins. The function of these are to act as a cellular receptor for cyclosporine A (Luo et al. 2004; Dawar et al. 2017). Cyclophilin
A facilitates or inhibits the replication of immunophilins in viral infections (Dawar et al. 2017). The inhibition of cyclophilins by using cyclosporine A might arrest the replication of coronaviruses such as SARS-CoV (Pfefferle et al. 2011), so the non-immunosuppressive cyclosporine A derivatives might have the potential as inhibitors against coronaviruses such as emerging newly COVID-19. Now, only 6 clinical trials are being carried out to reveal the efficacy of cyclosporine A against COVID-19 (NIH US National Library of Medicine clinical trial database, https://www.clinicaltrials.gov/ct2/results?cond=Covid19&term=cyclosporine+A&type=>&rslt=&&cntry=&&intr=&&titles=&&outc=&&spons=&&lead=&&id=&&city=&&state=&&dist=&&locn=&&rsub=&&strd_s=&&strd_e=&&prcd_s=&&prcd_e=&&sfpd_s=&&sfpd_e=&&rfpd_s=&&rfpd_e=&&lupd_s=&&lupd_e=&&sort=). However, the use of MSCs for the treatment of COVID-19 is not advised except in a clinical trial (NIH COVID-19 Treatment Guidelines, https://www.covid19treatmentguidelines.nih.gov/immune-based-therapy/blood-derived-products/mesenchymal-stem-cells/).

**Natural killer cells**

Natural killer (NK) cells are large granular lymphocytes and originated from bone marrow. Because NK cells have the ability to distinguish between normal cells and infected cells, it regulates a large number of immunological courses, for example, viral defense and immunological homeostasis. NK cells break down virus-infected cells by antibody-dependent cellular cytotoxicity (ADCC) process (Hammer et al. 2018). Therefore, NK cells show specificity to nearly all virus-infected cells. Some researches have indicated that NK cells can show antiviral efficiency against SARS-CoV, herpes simplex virus type 1 (HSV-1), cytomegalovirus, and HIV viruses through ADCC mediators (Dai and Caligiuri 2018; Arase et al. 2002; National Research Project for SARS, Beijing Group 2004).

Sorrento and Celularity declared that clinical cooperation has been started to be used CYNK-001, an allogeneic, off-the-shelf, obtained from navel cord blood NK cell therapy, as a new therapy method for the therapy and prevention of COVID-19 (Sorrento and Celularity to initiate emergency allogeneic NK cell therapy development for coronavirus infection Sorrento and Celularity to initiate emergency allogeneic NK cell therapy development for coronavirus infection). In order to rise immunity by using NK cell therapy until new treatment methods are found, NK cell therapy is of great importance against COVID-19 pneumonia so 28 clinical trials are underway about NK cell, at present (NIH US National Library of Medicine clinical trial database, https://www.clinicaltrials.gov/ct2/results?cond=Covid19&term=natural+killer+cell&type=&rslt=&&cntry=&&intr=&&titles=&&outc=&&spons=&&lead=&&id=&&city=&&state=&&dist=&&locn=&&rsub=&&strd_s=&&strd_e=&&prcd_s=&&prcd_e=&&sfpd_s=&&rfpd_e=&&lupd_s=&&sort=).

**Cellular therapy**

**Mesenchymal stem cells**

Mesenchymal stem cells (MSCs) are strong anti-inflammatory and immunomodulatory. Besides, it has been determined that MSCs could improve acute/chronic lung injury and acute respiratory distress syndrome (ARDS), because they suppress the leakage of immune cells to pulmonary tissues and pro-inflammatory cytokine secretion (Ortiz et al. 2007; Gupta et al. 2007; Moodley et al. 2009; Matthey et al. 2010). Furthermore, MSCs contribute to decreasing lung fibrosis as well as increasing tissue repair (Kumamoto et al. 2009; El Agha et al. 2017). The patients with severe COVID-19 infections suffer from cytokine storm syndromes, ARDS, and acute lung injury so MSCs may be an encouraging therapeutic option to prevent these complications. There are 55 clinical trials ongoing about MSCs, of them only 2 trials were finished, now (NIH US National Library of Medicine clinical trial database, https://www.clinicaltrials.gov/ct2/results?cond=Covid19&term=mesenchymal+stem+cell&type=&rslt=&&cntry=&&intr=&&titles=&&outc=&&spons=&&lead=&&id=&&city=&&state=&&dist=&&locn=&&rsub=&&strd_s=&&strd_e=&&prcd_s=&&prcd_e=&&sfpd_s=&&rfpd_s=&&rfpd_e=&&lupd_s=&&lupd_e=&&sort=).

**Antiviral drugs**

**Remdesivir**

Remdesivir (Fig. 4), a nucleotide analog GS-5734, has capable of being incorporated into the new viral RNA leading to early termination. This mechanism constitutes the
basis of the possible effectiveness of it against respiratory coronaviruses (Lombardy Section Italian Society Infectious and Tropical Diseases 2020). Remdesivir was determined to inhibit SARS-CoV and MERS-CoV in vivo (de Wit et al. 2020; Agostini et al. 2018). Lately, remdesivir has been shown to block SARS-CoV infection selectively at low-micromolar concentrations in vitro (Wang et al. 2020). Furthermore, when the patient with COVID-19 infection got worse, this patient was treated with remdesivir, intravenously in the USA (Holshue et al. 2020). Remdesivir has some benefits to treat COVID-19 infections, but randomized controlled trials are necessary to prove its activity and safety.

The suggested mechanism of remdesivir is the host cells’ post-entry stage (Wang et al. 2020). It was found that combined use of remdesivir and IFN-β created the higher antiviral activity compared to the lopinavir/ritonavir-IFN-β combination against MERS-CoV virus in vitro and in vivo. Additionally, remdesivir could be better pulmonary function, cause to fall lung viral loads and severe lung pathology in mice, on the contrary, lopinavir/ritonavir-IFN-β could not (Sheahan et al. 2020).

Two clinical studies regarding the use of remdesivir have been carried out against severe or mild respiratory infections caused by COVID-19 (ClinicalTrials.gov [Internet] 2020c; NCT04252664 2020). Dyer et al. (2019) has shown that initial findings of a death rate were 33% in 499 patients under treatment by using remdesivir against the Ebola disease. Moreover, the mortality rate of non-treated infected patients was 75% (almost 1900 people) during the same epidemic period.

Recently, it was proclaimed that the United States Food and Drug Administration (FDA) approved remdesivir for emergency use to treat COVID-19 pneumonia (The FDA has approved emergency use of remdesivir to treat COVID-19).

Meanwhile, a molecular docking study including five antiviral drugs, ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir was conducted against SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), these drugs showed promising results against COVID-19. Further optimization of these agents using a high-quality model of the SARS-CoV-2 RdRp might be useful for designing perfect compounds able to prevent this spreading infection (Elfyky 2020).

Now, 44 clinical trials are being carried out to reveal the efficacy of this drug against COVID-19, of them 5 trials were completed (NIH US National Library of Medicine clinical trial database, https://clinicaltrials.gov/ct2/results?cond=Covid19&term=remdesivir&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&loca=&rsid=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=). Considering the patient’s supplemental oxygen necessities and the manner of oxygen delivery, the use of remdesivir has been changed in the therapy of COVID-19 in July (NIH COVID-19 Treatment Guidelines, https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/remdesivir/).

**Lopinavir/ritonavir**

Lopinavir and ritonavir (Fig. 4) that inhibit the HIV-protease enzyme are antiretroviral drugs used for AIDS treatment. It is known that as a result of the combined use of ritonavir, which is used in low doses to increase the
effectiveness of lopinavir, it decreases the mortality and morbidity values in HIV patients (Lombardy Section Italian Society Infectious and Tropical Diseases 2020).

Lin et al. (2020), reported that lopinavir and ritonavir could connect to the SARS-CoV-2 protease in the modeling study. This offers that lopinavir/ritonavir could be effective by inhibiting SARS-CoV-2 protein synthesis. Furthermore, several findings proved that treatment with lopinavir/ritonavir alone or in combination together with other antiviral agents developed severe patients with SARS or MERS (Chu et al. 2004; Sheahan et al. 2020; Zumla et al. 2016).

The combination of lopinavir/ritonavir and ribavirin has improved the course of the disease in SARS-CoV patients (Chu et al. 2004).

In other combination studies with lopinavir/ritonavir, ribavirin and IFN-α2a carried out in South Korea, a patient with MERS-CoV disease has been successfully treated (Kim et al. 2016). Now, lopinavir/ritonavir and IFN-β1b is in phase 2 for the MERS therapy in a randomized controlled trial (Arabi et al. 2018). Similarly, the therapeutic efficacy of the same combination is being investigated in a sequential randomized controlled trial (Arabi et al. 2020).

Despite the positive findings mentioned above, according to a recent study performed on patients with SARS-CoV-2 infection, it has been suggested that the lopinavir/ritonavir combination did not provide the clinical improvement compared to standard care processes (Cao et al. 2020). Actually, findings of lopinavir/ritonavir clinical efficacy remain limited and primarily anecdotal cases (Han et al. 2019). Although COVID-19 viral load can be decreased via lopinavir/ritonavir application very fast (Lim et al. 2020), the use of this combination for the therapy of COVID-19 is not advised by the COVID-19 Treatment Guidelines Panel except in a clinical trial (NIH COVID-19 Treatment Guidelines, https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/lopinavir-ritonavir-and-other-hiv-protease-inhibitors/).

Further research related the clinical efficacy about lopinavir/ritonavir combination in the therapy of COVID-19 is needed as current results contradict so 81 clinical trials were completed using danoprevir combined with ritonavir in the treatment of SARS-CoV-2 infection in China (NIH US National Library of Medicine clinical trial database, https://clinicaltrials.gov/ct2/results?cond=Covid19&term=da

Favipiravir

Favipiravir (Fig. 4) is a new antiviral drug that inhibits RNA-dependent RNA polymerase (RdRp). It was approved for use against novel influenza in February 2020 in China. Besides, its anti-influenza virus action, it stops the replication of RNA viruses such as flavi-, alpha-, flifo-, bunya-, arena-, noroviruses (Delang et al. 2018). Favipiravir is a pro-drug which is converted into an active phosphoribosylated form (Favipiravir-RTP) in cells, then viral RNA polymerase identifies it as a substrate, resulting in inhibiting RNA polymerase function (Furuta et al. 2017). Eventually, favipiravir may have a potent antiviral activity for the therapy of COVID-19. The promising outcomes were achieved in a clinical trial with favipiravir against COVID-19 in China. The preliminary results from this study involving 80 patients (a total of the experimental and the control group) stated that favipiravir showed a more powerful antiviral activity than that of lopinavir/ritonavir. Adverse reactions did not observe in favipiravir therapy group considerably. Compared to the lopinavir/ritonavir group, it had considerably fewer adverse effects (https://www.szdsyy.com/News/0a6c1e58-e3d0-4cd1-867a-d5524bc59cd6.html).

Presently, 32 clinical trials are being carried out for using favipiravir in the treatment of COVID-19, of them 6 trials were completed and it is expected that promising results will be achieved in removing the virus (NIH US National Library of Medicine clinical trial database, https://clinicaltrials.gov/ct2/results?cond=Covid19&term=favipira

Danoprevir

Danoprevir (Fig. 4, approved in China for the therapy of non-cirrhotic genotype 1b chronic hepatitis C together with some drugs, is a HCV N53 protease inhibitor. Only two clinical trials were completed using danoprevir combined with ritonavir in the treatment of SARS-CoV-2 infection in China (NIH US National Library of Medicine clinical trial database, https://clinicaltrials.gov/ct2/results?cond=Covid19&term=da

Darunavir

Darunavir (Fig. 4) boosted with ritonavir or cobicistat are currently used for in HIV/AIDS treatment approved by the
FDA. Thus, the pharmacokinetics and pharmacodynamics of darunavir or ritonavir are enhanced by cytochrome p450 (CYP3A) inhibition (Mathias et al. 2010; Santos et al. 2019). Cell experiments with darunavir showed that the drug inhibited viral replication of COVID-19 in vitro, significantly (News: Abidol and darunavir can effectively inhibit coronavirus. Although lopinavir/ritonavir used in the treatment of HIV/AIDS, has more efficacy and tolerability than darunavir, its use in COVID-19 is limited (Lombardy Section Italian Society Infectious and Tropical Diseases 2020). Currently, there are nine clinical trials at different phases of development on the efficacy of darunavir in the treatment of COVID-19 pneumonia (NIH US National Library of Medicine clinical trial database, https://clinicaltrials.gov/ct2/results?cond=Covid19&term=darunavir&type= &rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&rsrb=&strd_s=&strd_e=&prcd_s=&&&sfpd_s=&rfpd_e=&&rupd_e=&&sort=).

**Ribavirin**

Ribavirin (Fig. 4), has a broad-spectrum agent against virus diseases, is a nucleoside analog. It suppresses the action of inosine monophosphate dehydrogenase, thus, the synthesis of guanosine triphosphate (GTP) is affected, so the replication of RNA and DNA viruses could be prevented. Ribavirin was widely used during the outbreak of SARS in Hong Kong. For this, it was sometimes preferred with or without steroids (Wenzel and Edmond 2003; Jones et al. 2004; Peiris et al. 2003). The combination of ribavirin and interferon-β, which appears to inhibit SARS-CoV replication, has shown significant efficacy in the inhibition of SARS-CoV (Morgenstern et al. 2005). Ribavirin is being searched in 12 clinical trials, and 3 of them were completed, now (NIH US National Library of Medicine clinical trial database, https://clinicaltrials.gov/ct2/results?cond=Covid19&term=ribavirin&type= &rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&rsrb=&strd_s=&strd_e=&prcd_s=&&&sfpd_s=&rfpd_e=&&rupd_e=&&sort=). In one of the completed clinical trials, Hung et al. (2020) reported that the ribavirin triple antiviral treatment was safe and superior compared to lopinavir-ritonavir combined therapy.

**Arbidol (umifenovir)**

Arbidol (Fig. 4) is an antiviral agent that has indol-derivative compound and is registered in Russia and China for prophylaxis and therapy of influenza and other respiratory viral infections. This drug prevents fusion between the virus and the cell membrane that is an important stage in the entry of the virus into the cell (Blaising et al. 2014). And also, it blocks hepatitis virus entry and replication in vitro (Pécheur et al. 2016). Arbidol and its derivative, arbidol mesylate, showed antiviral activity against SARS-CoV because they declined the reproduction of the virus in the cell cultures (Khamitov et al. 2008). Based on a few findings, arbidol tested alone or with some antiviral agents against COVID-19, and certain positive effects were observed (Wang et al. 2020; Zhang et al. 2020; Xu et al. 2020). Currently, arbidol alone or in combination with some antiviral drugs are tested through ten clinical trials, of them only one trial was completed (NIH US National Library of Medicine clinical trial database, https://clinicaltrials.gov/ct2/results?cond=Covid19&term=arbidol&type= &rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&rsrb=&strd_s=&strd_e=&prcd_s=&&&sfpd_s=&rfpd_e=&&rupd_e=&&sort=).

**Neuraminidase inhibitors**

Oseltamivir, zanamivir, and peramivir (Fig. 5) are antiviral drugs that inhibit the viral neuraminidase enzyme and block the release of viral particles out of host cells (Uyeki 2018). These agents called neuraminidase inhibitors are recommended for influenza (Chow et al. 2019). Neuraminidase inhibitors have been used as an empirical treatment in MERS-CoV infection (Bleibtreu et al. 2018). Furthermore, it was reported that oseltamivir has been used either with or without antibiotics and corticosteroids against COVID-19 (Wang et al. 2020). In a clinical trial, oseltamivir is tested with chloroquine and favipiravir (ClinicalTrials.gov

![Fig. 5 Chemical formulas of neuraminidase inhibitors](image-url)
Chloroquine and hydroxychloroquine (Fig. 6) have been utilized against malaria for years. Besides, this chemical usage, they show antiviral effects against HIV. Their mechanism of action is to inhibit the virus entry into host cells. The second antiviral mechanism is thought to be relevant to the post-translation modification of freshly synthesized proteins over glycosylation inhibition (Rolain et al. 2007).

Chloroquine and hydroxychloroquine blocked viral replication at multiple points in vitro experiments so these drugs have been found to be effective against SARS-CoV-2. Primarily, they come together in lysosomes, increase endosomal pH, and cut off the lysosome-endosome fusion. Therefore, the transport of virus is blocked (Yao et al. 2020). Furthermore, chloroquine and hydroxychloroquine have been determined to interfere with the angiotensin-converting enzyme 2 (ACE2) receptor, which has an important receptor for the attachment of COVID-19 into the cell by cell-surface protein glycosylation (Fantini et al. 2020). In addition, it was shown that chloroquine had higher efficacy than hydroxychloroquine (Liu et al. 2020).

Hydroxychloroquine combined with the macrolide antibiotic azithromycin cured 100% of patients with COVID-19 in a trial, lately. However, hydroxychloroquine alone cured only 57.1% of patients (Gautret et al. 2020). Nowadays, the efficacy of chloroquine and hydroxychloroquine will be tried in people with COVID-19 (National Library of Medicine (US), Bethesda (MD) 2020) in the healthcare setting (COPCOV) (ClinicalTrials.gov [Internet] 2020e), and chloroquine as preventative medicine against COVID-19. Now, 246 clinical trials are being carried out with hydroxychloroquine, of them 21 trials were completed (NIH US National Library of Medicine clinical trial database, https://clinicaltrials.gov/ct2/results?cond=Covid19&term=hydroxychloroquine&type=&rlst=&age_v=&gnrdr=&intr=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locln=&rsbd=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rldpd_s=&rldpd_e=&lupd_s=&lupd_e=&sort=).

### Other drugs

**Chloroquine and hydroxychloroquine**

Chloroquine and hydroxychloroquine have been found to be effective against SARS-CoV-2. Primarily, they come together in lysosomes, increase endosomal pH, and cut off the lysosome-endosome fusion. Therefore, the transport of virus is blocked (Yao et al. 2020). Furthermore, chloroquine and hydroxychloroquine have been determined to interfere with the angiotensin-converting enzyme 2 (ACE2) receptor, which has an important receptor for the attachment of COVID-19 into the cell by cell-surface protein glycosylation (Fantini et al. 2020). In addition, it was shown that chloroquine had higher efficacy than hydroxychloroquine (Liu et al. 2020).

Hydroxychloroquine combined with the macrolide antibiotic azithromycin cured 100% of patients with COVID-19 in a trial, lately. However, hydroxychloroquine alone cured only 57.1% of patients (Gautret et al. 2020). Nowadays, the efficacy of chloroquine and hydroxychloroquine will be tried in people with COVID-19 (National Library of Medicine (US), Bethesda (MD) 2020) in the healthcare setting (COPCOV) (ClinicalTrials.gov [Internet] 2020e), and chloroquine as preventative medicine against COVID-19. Now, 246 clinical trials are being carried out with hydroxychloroquine, of them 21 trials were completed (NIH US National Library of Medicine clinical trial database, https://clinicaltrials.gov/ct2/results?cond=Covid19&term=hydroxychloroquine&type=&rlst=&age_v=&gnrdr=&intr=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locln=&rsbd=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rldpd_s=&rldpd_e=&lupd_s=&lupd_e=&sort=).

The antiviral activity of chloroquine phosphate has been shown against the SARS virus and avian flu in clinical studies in vitro and animal models (Savarino et al. 2006; Vincent et al. 2005; Yan et al. 2013). Because chloroquine has immunomodulatory action, this effect could enhance its antiviral activity in vivo. Chloroquine penetrates into the tissues well after oral administration. It was declared in February 2020 in China, the use of chloroquine improved the rate of clinical success, with a reduction of hospitalization and the improvement of the patient’s outcome (Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia 2020). Presently, 84 clinical trials are being conducted with chloroquine, of them 9 trials were at the completed stage (NIH US National Library of Medicine clinical trial database, https://clinicaltrials.gov/ct2/results?cond=Covid19&term=chloroquine&type=&rlst=&age_v=&gnrdr=&intr=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locln=&rsbd=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rldpd_s=&rldpd_e=&lupd_s=&lupd_e=&sort=).

Since clinical data about the use of chloroquine and hydroxychloroquine in the treatment of COVID-19 pneumonia with severe and critical conditions is very limited, the COVID-19 Treatment Guidelines Panel does not advise the usage of these drugs in therapy, except in a clinical trial (NIH COVID-19 Treatment Guidelines, https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/chloroquine-or-hydroxychloroquine/).

**Methylprednisolone**

Corticosteroid therapy (methylprednisolone (Fig. 7), dexamethasone, and hydrocortisone) has been shown to be useful for the therapy of SARS-CoV patients. This therapy method extended the survival period of clinical cases, significantly (Long et al. 2016). On the contrary, other researchers claimed that when corticosteroids used in the early steps of SARS infections it caused to increase values of viral load (Lee et al. 2004). Besides, researchers where corticosteroids in the adjuvant therapy against MERS-CoV...
infections could not show the efficacy due to the death of all patients (Al-Tawfiq and Memish 2017). Previously, methylprednisolone has been used with antibiotics, oseltamivir, and oxygen therapy against COVID-19 (Huang et al. 2020).

Currently, a total of 32 clinical trials are underway with methylprednisolone in the treatment of COVID-19, of them 6 trials were completed (NIH US National Library of Medicine clinical trial database, https://clinicaltrials.gov/ct2/results?cond=Covid19&term=methylprednisolone&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&sfpd_s=&sfpd_e=&rfpd_s=&lupd_s=&lupd_e=&sort=).

**Thalidomide**

Thalidomide (Fig. 7) speeds up the deterioration of mRNA in blood cells, consequently shows anti-inflammatory activity. And also, it reduces TNF-α activity. And also, it reduces TNF-α in blood cells, consequently shows anti-inflammatory activity (Newfield 2018). Now, only 5 clinical trials are being conducted by researchers on thalidomide (NIH US National Library of Medicine clinical trial database, https://clinicaltrials.gov/ct2/results?cond=Covid19&term=thalidomide&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&sfpd_s=&sfpd_e=&rfpd_s=&lupd_s=&lupd_e=&sort=).

**Pirfenidone**

Pirfenidone (Fig. 7) having anti-inflammatory and anti-oxidant activities have been used against idiopathic pulmonary fibrosis diseases, so far. Additionally, it inhibits IL-1β and IL-4, https://clinicaltrials.gov/ct2/show/NCT04282902?term=NCT04282902&draw=2&rank=1. Probably, its anti-inflammatory effects might be beneficial, but there are no clinical trials on pirfenidone, at present.

**Bromhexine**

Bromhexine (Fig. 7) inhibits a transmembrane protease serine that is responsible for the activation of S-glycoprotein found in SARS and MERS viruses. This glycoprotein provides the entry of the virus through the plasma membrane so 5 clinical trials are carried out on the efficacy of bromhexine against COVID-19 cases (NIH US National Library of Medicine clinical trial database, https://clinicaltrials.gov/ct2/results?cond=Covid19&term=bromhexine&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=)

**Vitamin C**

Vitamin C (Fig. 7) is a water-soluble vitamin and known as ascorbic acid also. Because of its antioxidant efficiency, it may have a reducing effect on oxidative stress and inflammation (ClinicalTrials.gov [Internet] 2020f; Kashour et al. 2020). It has been revealed that vitamin C supported immune functions and protected against coronavirus infections (Hemila 2003). In human-controlled trials, vitamin C decreased the incidence of pneumonia, significantly. Thus, it was thought that vitamin C may be an anti-sensitiveness compound that prevents the sensitivity to lower respiratory tract infections under particular situations (Hemili 1997). As of now, 32 clinical trials were being carried out on vitamin C, of them only 1 was completed (NIH US National Library of Medicine clinical trial database, https://clinicaltrials.gov/ct2/results?cond=Covid19&term=thalidomide&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&sfpd_s=&sfpd_e=&rfpd_s=&lupd_s=&lupd_e=&sort=).

Since there are not enough data, it is not recommended to use or not use vitamin C in the treatment of COVID-19 patients (NIH COVID-19 Treatment Guidelines, https://www.covid19treatmentguidelines.nih.gov/adjunctive-therapy/vitamin-c/).
Carrimycin (Fig. 7) is a macrolide class antibiotic and it is effective against some gram-positive bacteria, and Mycobacterium tuberculosis in vitro (Wang et al. 2019). The drug has been used for the therapy of patients with COVID-19 in a clinical study (NIH US National Library of Medicine clinical trial database, https://www.clinicaltrials.gov/ct2/show/NCT04286503?term=carrimycin&cond=Covid19&draw=2&rank=1).

Chinese medicine

The active compounds found in Chinese medicine, such as glycyrrhizin, hesperetin, baicalin, and quercetin (Fig. 8) are thought as considerable compounds in the prevention and treatment of COVID-19 disease (Li et al. 2020).

Glycyrrhizin (Fig. 8), which is the active compound of liquorice roots used in Chinese medicine, can inhibit the transcription of SARS virus in vitro trials (Cinatl et al. 2003; Hoever et al. 2005). Lately, it was found that glycyrrhizin can bind to the ACE2 receptor (Chen and Du 2020). When given high doses of glycyrrhizin, it was clinically effective in clinical trials against the SARS virus (Lu et al. 2003; Wu et al. 2004). Moreover, it has been revealed that glycyrrhizin may inhibit the transcription of SARS-associated virus in vitro (Cinatl et al. 2003; Hoever et al. 2005). Only one clinical trial is carried out about glycyrrhizin, now (NIH US National Library of Medicine clinical trial database, https://clinicaltrials.gov/ct2/results?cond=Covid19&term=Glycyrrhizin&type=&rslt=&age_v=&gndr=&intr=&title=&outc=&spons=&lead=&id=&cnty=&state=&city=&dist=&locn=&sub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=).

Imatinib

Blocking virus–host fusion is a promising target for the discovering of novel antiviral agents, so there are some studies on drugs that inhibit the Abl kinase pathway (Dong et al. 2020). In a study, imatinib, an Abl kinase inhibitor, was observed to block the replication of SARS and MERS viruses by blocking viral fusion in 2016 (Coleman et al. 2016). Hoffman et al. (2020) also showed that the COVID-19 used the SARS-coronavirus receptor ACE2 as well as the cellular protease TMPRSS2 for accessing into target cells, so TMPRSS2, transmembrane serine protease 2, inhibitory agents such as imatinib may be evaluated as therapy options for COVID-19 disease. And five clinical trials are underway on the safety and efficacy of imatinib for the treatment of COVID-19 pneumonia, at present (NIH US National Library of Medicine clinical trial database, https://clinicaltrials.gov/ct2/results?cond=Covid19&term=imatinib&type=&rslt=&age_v=&gndr=&intr=&title=&outc=&spons=&lead=&id=&cnty=&state=&city=&dist=&locn=&sub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=).

Carrimycin

Carrimycin (Fig. 7) is a macrolide class antibiotic and it is effective against some gram-positive bacteria, and Mycobacterium tuberculosis in vitro (Wang et al. 2019). The drug has been used for the therapy of patients with COVID-19 in a clinical study (NIH US National Library of Medicine clinical trial database, https://www.clinicaltrials.gov/ct2/show/NCT04286503?term=carrimycin&cond=Covid19&draw=2&rank=1).

Chinese medicine

The active compounds found in Chinese medicine, such as glycyrrhizin, hesperetin, baicalin, and quercetin (Fig. 8) are thought as considerable compounds in the prevention and treatment of COVID-19 disease (Li et al. 2020).

Glycyrrhizin (Fig. 8), which is the active compound of liquorice roots used in Chinese medicine, can inhibit the transcription of SARS virus in vitro trials (Cinatl et al. 2003; Hoever et al. 2005). Lately, it was found that glycyrrhizin can bind to the ACE2 receptor (Chen and Du 2020). When given high doses of glycyrrhizin, it was clinically effective in clinical trials against the SARS virus (Lu et al. 2003; Wu et al. 2004). Moreover, it has been revealed that glycyrrhizin may inhibit the transcription of SARS-associated virus in vitro (Cinatl et al. 2003; Hoever et al. 2005). Only one clinical trial is carried out about glycyrrhizin, now (NIH US National Library of Medicine clinical trial database, https://clinicaltrials.gov/ct2/results?cond=Covid19&term=Glycyrrhizin&type=&rslt=&age_v=&gndr=&intr=&title=&outc=&spons=&lead=&id=&cnty=&state=&city=&dist=&locn=&sub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=).

Imatinib

Blocking virus–host fusion is a promising target for the discovering of novel antiviral agents, so there are some studies on drugs that inhibit the Abl kinase pathway (Dong et al. 2020). In a study, imatinib, an Abl kinase inhibitor, was observed to block the replication of SARS and MERS viruses by blocking viral fusion in 2016 (Coleman et al. 2016). Hoffman et al. (2020) also showed that the COVID-19 used the SARS-coronavirus receptor ACE2 as well as the cellular protease TMPRSS2 for accessing into target cells, so TMPRSS2, transmembrane serine protease 2, inhibitory agents such as imatinib may be evaluated as therapy options for COVID-19 disease. And five clinical trials are underway on the safety and efficacy of imatinib for the treatment of COVID-19 pneumonia, at present (NIH US National Library of Medicine clinical trial database, https://clinicaltrials.gov/ct2/results?cond=Covid19&term=imatinib&type=&rslt=&age_v=&gndr=&intr=&title=&outc=&spons=&lead=&id=&cnty=&state=&city=&dist=&locn=&sub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=).

Carrimycin

Carrimycin (Fig. 7) is a macrolide class antibiotic and it is effective against some gram-positive bacteria, and Mycobacterium tuberculosis in vitro (Wang et al. 2019). The drug has been used for the therapy of patients with COVID-19 in a clinical study (NIH US National Library of Medicine clinical trial database, https://www.clinicaltrials.gov/ct2/show/NCT04286503?term=carrimycin&cond=Covid19&draw=2&rank=1).
cell-free as well as cell-based tests (Lin et al. 2005). 3CLpro is the viral parent protease that checks the actions of the coronavirus replication complex, thus it is an appealing target for treatment (3CLpro). Another study reported that hesperetin had the potential to inhibit ACE2 (Chen and Du 2020). For these reasons, it seems that hesperetin has the potential to block SARS-CoV infection.

Baicalin (Fig. 8) is one of the other active compounds used as Chinese medicine. Chen et al. (2004) revealed that baicalin can inhibit the SARS virus in vitro (Chen et al. 2004).

Quercetin (Fig. 8) which is widely used in Chinese medicine is a flavone obtained from plants. Quercetin inhibits the 3CLpro of the SARS virus, thus, blocks the accessing of the SARS virus into host cells (Yi et al. 2004). Currently, two clinical trials are being conducted to evaluate the efficacy of quercetin in COVID-19 patients (NIH US National Library of Medicine clinical trial database, https://clinicaltrials.gov/ct2/results?cond=Covid19&term=vaccine&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&lcn=&rsup=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=). In view of these works, Chinese medicine can play a primary role in the therapy and prevention of COVID-19 disease.

**Vaccines**

Vaccination offers a very convenient tool to prevent and to inhibit the infectious diseases spread. The vaccines stimulate humoral immune responses, in this way, neutralizing antibodies are started to be produced in the human body. Thus, it is possible to both control infection and prevents reinfection. Vaccine development studies are continuing as well as any discovery of new drug or development treatment method to treat COVID-19 pneumonia. Revealing the genome sequence of SARS-CoV-2 has accelerated vaccine development studies. The methods used for developing the SARS-CoV-2 vaccine are the same as those used for the SARS-CoV vaccine. Both viruses bind the same host cell receptor (ACE2). In addition to this, they can share similar disease pathogeneses as well as restricted cross-neutralizing antibodies (Devaux et al. 2020; Shih et al. 2020). As of now (August 20, 2020), a total of 193 clinical trials are being conducted to develop a vaccine against COVID-19, of them 8 were at the completed stage (NIH US National Library of Medicine clinical trial database, https://clinicaltrials.gov/ct2/results?cond=Covid19&term=vaccine&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&lcn=&rsup=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=).

Information about the vaccine candidates against COVID-19 is presented at Table 1 (NIH US National Library of Medicine clinical trial database, https://clinicaltrials.gov/ct2/results?cond=Covid19&term=vaccine&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&lcn=&rsup=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=).

**Conclusion**

The outbreak began with SARS-CoV in the year of 2002 firstly, then, extended to 32 countries and regions. Following one decade, the World encountered MERS-CoV, another coronavirus. Nowadays, the rising SARS-CoV-2 turned into a global threat so the WHO proclaimed that the COVID-19 outbreak was a global pandemic in March 2020.

COVID-19, previously known as SARS-CoV-2, targets lung cells by connecting to ACE2 protein. This protein is largely produced in some tissues such as bile duct, liver, gastrointestinal organs (e.g., small intestine, duodenum), esophagus, testis, and kidney as well as lung tissue (Zhang et al. 2020; Chai et al. 2020; Anti-2019-nCoV Volunteers et al. 2020; Fan et al. 2020). Thus, COVID-19 may damage these organs and tissues. Now, COVID-19 has extended to various countries speedily, caused severe sickness and these events made it a relevant and considerable public health-threatening. Taking into account the global threatening caused by COVID-19, efficient therapy methods against COVID-19 disease are promptly necessary. Nevertheless, the development of new agents for this disease is still a considerable problem for people in the world, and we have none formally approved agents against COVID-19 pneumonia now. Looking at the epidemiological properties of COVID-19, it is very important to cut off the extending of this virus owing to epidemic prevention as well as checking procedures. For this, the most recommended preventions are putting infected people in quarantine and checking the source of infection. The limited information available we have is needed to develop novel drugs and to find new therapy methods to prevent this outbreak and to treat COVID-19 pneumonia. Furthermore, the design and improvement of vaccines against COVID-19 are also necessary as well as discovering novel agents and clinical trials of known drugs.

In this review, we focused on some medicines that have already started with the repositioning for COVID-19 therapy. The repositioning clinical trials seem to be an attractive strategy, thus, the discovery of new classes of drug can be...
easier, the costs and time for reaching the market can decrease, the pharmaceutical supply chain is available for formulation and distribution, more therapy methods are possible by combining the drugs. We hope that the continuing studies may provide solutions for the prevention and therapy against the COVID-19 pandemic in 2020.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**References**

Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R, Ray AS, Cihlar T, Siegel D, Mackman RL, Clarke MO, Baric RS, Denison MR (2018) Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9:e00221–e002218

Al-Tawfiq JA, Memish ZA (2017) Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Expert Rev Anti Infect Ther 15:269–275

Anti-2019-nCoV Volunteers, Li Z, Wu M, Yao J, Guo J, Liao X, Song Aj, Arbaei YM, Asiri AY, Assiri AM, Jokhdar HAA, Alothman A, Balkhy HH, Hajeer AH, Bouchama A, Hayden FG, Al-Omari GA, Sherbeeni NM, Elzein FE, Memon J, Taha Y, Alzahrani A, Al-Johani S, Al-Jerai A, Banerjee A, Kulcsar K, Misra V, Frieman M, Mossman K (2019) Bats and coronaviruses. Viruses 11:pii: E41

Banerjee A, Kulcsar K, Misra V, Frieman M, Mossman K (2019) Bats and coronaviruses. Viruses 11:pii: E41

National Library of Medicine (US): Bethesda (MD) (2020) Mar 12–Identifier NCT04303507. Chloroquine prevention of Coronavirus disease (COVID-19) in the healthcare setting (COP-COV). https://clinicaltrials.gov/ct2/show/NCT04303507?term=NCT04303507&draw=2&rank=1. Accessed 15 Feb 2020

Blaising J, Poljak SJ, Pécheur El (2014) Arbidol as a broad-spectrum antiviral: an update. Antivir Res 107:84–94

Bleibtreu A, Jaureguyberrir S, Houhou N, Boutolleau D, Guillot H, Vallois D, Lucet JC, Robert J, Mouvillier B, Delemazure J, Jaspard M, Lescure FX, Rioux C, Caumes Y, Yazdanapanah Y (2018) Clinical management of respiratory syndrome in patients hospitalized for suspected Middle East respiratory syndrome coronavirus infection in the Paris area from 2013 to 2016. BMC Infect Dis 18:331

BuzzFeedNews. The FDA has approved emergency use of remdesivir to treat COVID-19. https://www.buzzfeednews.com/article/danvergano/fda-remdesivir-coronavirus. Accessed 2 May 2020

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Geng F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Yang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Fan P, Lou Z, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C (2020) A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. https://doi.org/10.1056/NEJMoa2001282

Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A, Zhou J, Shi G, Fang N, Fan J, Cai J, Fan J, Lan F (2020) Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv. https://doi.org/10.1101/2020.02.03.931766

Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, Yuen KY (2020) Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 9:221–236

Chen F, Chan KH, Jiang Y, Kao RYT, Lu HT, Fan KW, Cheng VCC, Tsui WHW, Hung IFN, Lee TSW, Guan Y, Peiris JSM, Yuen KY (2004) In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol 31:69–75

Chen H, Du Q (2020) Potential natural compounds for preventing 2019-nCoV infection. Preprints 2020:2020010358

Cheng Y, Wong R, Sso YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB, Cheng G (2005) Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 24:44–46

Cherin P, Marie I, Michallet M, Pelus E, Dantal J, Crave JC, Delain JC, Viallard JF (2016) Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence. Autoimmun Rev 15:71–81

Chow EJ, Doyle JD, Uyeki TM (2019) Influenza virus-related critical illness: prevention, diagnosis, treatment. Crit Care 23:214

Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, Kao KY, Poon LL, Wong CL, Guan Y, Peiris JS, Yuen KY, HKU/UCH SARS Study Group (2004) Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59:252–256
Guangdong Province for Chloroquine in the Treatment Of Novel Coronavirus Pneumonia (2020) Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Xi Za Zhi 43:E019

Mustafa S, Balkhy H, Gabere MN (2018) Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): a review. J Infect Public Health 11:9–17

Nassar MS, Bakhrehab MA, Mee SA, Alsuabeyl MS, Zaher WA (2018) Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics. Eur Rev Med Pharm Sci 22:4956–4961

Natural Research Project for SARS, Beijing Group (2004) The involvement of natural killer cells in the pathogenesis of severe acute respiratory syndrome. Am J Clin Pathol 121:507–511

Newfield C (2018) New medical indications for thalidomide and its derivatives. Sci J Lander College Arts Sci 12:11–19

News. Abidol and darunavir can effectively inhibit coronavirus. https://www.sd.chinanews.com/2020/0205/70145.html. Accessed 21 Feb 2020

News. Glenmark begins Phase-3 clinical trials on antiviral drug Favipiravir for COVID-19 patients in India. https://www.thehindu.com/news/national/glenmark-begins-phase-3-clinical-trials-on-antiviral-drug-favipiravir-for-coronavirus-patientsin-india/article31563918.ece. Accessed 25 May 2020

NIH COVID-19 Treatment Guidelines. https://clinicaltrials.gov/ct2/show/NCT04252664. Accessed 18 Feb 2020

NIH COVID-19 Treatment Guidelines. https://clinicaltrials.gov/ct2/show/NCT04252664. Accessed 18 Aug 2020

NIH COVID-19 Treatment Guidelines. https://clinicaltrials.gov/ct2/show/NCT04252664. Accessed 18 Aug 2020

NIH COVID-19 Treatment Guidelines. https://clinicaltrials.gov/ct2/show/NCT04252664. Accessed 18 Aug 2020

NIH COVID-19 Treatment Guidelines. https://clinicaltrials.gov/ct2/show/NCT04252664. Accessed 18 Aug 2020

NIH COVID-19 Treatment Guidelines. https://clinicaltrials.gov/ct2/show/NCT04252664. Accessed 18 Aug 2020

NIH US National Library of Medicine clinical trial database. https://clinicaltrials.gov/ct2/results?cond=Covid19&term=chloroquine&tipo=&rslt=&age_v=&gndr=&intr=&&outc=&spons=&lead=&id=cnty=&state=city=&dist=locln=&sub=&strd_s=&prcd_s=&rfd_e=&sfpd_s=&lupd_s=&lupd_e=&sort=. Accessed 18 Aug 2020

NIH US National Library of Medicine clinical trial database. https://clinicaltrials.gov/ct2/results?cond=Covid19&term=convalescent+plasma&type=&rslt=&age_v=&gndr=&intr=&&outc=&spons=&lead=&id=cnty=&state=city=&dist=locln=&sub=&strd_s=&prcd_s=&rfd_e=&sfpd_s=&lupd_s=&lupd_e=&sort=. Accessed 21 Aug 2020

NIH US National Library of Medicine clinical trial database. https://clinicaltrials.gov/ct2/results?cond=Covid19&term=cyclosporine+A&type=&rslt=&age_v=&gndr=&intr=&&outc=&spons=&lead=&id=cnty=&state=city=&dist=locln=&sub=&strd_s=&prcd_s=&rfd_e=&sfpd_s=&lupd_s=&lupd_e=&sort=. Accessed 21 Aug 2020

NIH US National Library of Medicine clinical trial database. https://clinicaltrials.gov/ct2/results?cond=Covid19&term=bevacizumab&type=&rslt=&age_v=&gndr=&intr=&&outc=&spons=&lead=&id=cnty=&state=city=&dist=locln=&sub=&strd_s=&prcd_s=&rfd_e=&sfpd_s=&lupd_s=&lupd_e=&sort=. Accessed 21 Aug 2020

NIH US National Library of Medicine clinical trial database. https://clinicaltrials.gov/ct2/results?cond=Covid19&term=bevacizumab&type=&rslt=&age_v=&gndr=&intr=&&outc=&spons=&lead=&id=cnty=&state=city=&dist=locln=&sub=&strd_s=&prcd_s=&rfd_e=&sfpd_s=&lupd_s=&lupd_e=&sort=. Accessed 21 Aug 2020

NIH US National Library of Medicine clinical trial database. https://clinicaltrials.gov/ct2/results?cond=Covid19&term=tinib&type=&rslt=&age_v=&gndr=&intr=&&outc=&spons=&lead=&id=cnty=&state=city=&dist=locln=&sub=&strd_s=&prcd_s=&rfd_e=&sfpd_s=&lupd_s=&lupd_e=&sort=. Accessed 21 Aug 2020

NIH US National Library of Medicine clinical trial database. https://clinicaltrials.gov/ct2/results?cond=Covid19&term=hydroxychloroquine&type=&rslt=&age_v=&gndr=&intr=&&outc=&spons=&lead=&id=cnty=&state=city=&dist=locln=&sub=&strd_s=&prcd_s=&rfd_e=&sfpd_s=&lupd_s=&lupd_e=&sort=. Accessed 21 Aug 2020

NIH US National Library of Medicine clinical trial database. https://clinicaltrials.gov/ct2/results?cond=Covid19&term=hydroxychloroquine&type=&rslt=&age_v=&gndr=&intr=&&outc=&spons=&lead=&id=cnty=&state=city=&dist=locln=&sub=&strd_s=&prcd_s=&rfd_e=&sfpd_s=&lupd_s=&lupd_e=&sort=. Accessed 21 Aug 2020

NIH US National Library of Medicine clinical trial database. https://clinicaltrials.gov/ct2/results?cond=Covid19&term=hydroxychloroquine&type=&rslt=&age_v=&gndr=&intr=&&outc=&spons=&lead=&id=cnty=&state=city=&dist=locln=&sub=&strd_s=&prcd_s=&rfd_e=&sfpd_s=&lupd_s=&lupd_e=&sort=. Accessed 21 Aug 2020

NIH US National Library of Medicine clinical trial database. https://clinicaltrials.gov/ct2/results?cond=Covid19&term=hydroxychloroquine&type=&rslt=&age_v=&gndr=&intr=&&outc=&spons=&lead=&id=cnty=&state=city=&dist=locln=&sub=&strd_s=&prcd_s=&rfd_e=&sfpd_s=&lupd_s=&lupd_e=&sort=. Accessed 21 Aug 2020

NIH US National Library of Medicine clinical trial database. https://clinicaltrials.gov/ct2/results?cond=Covid19&term=hydroxychloroquine&type=&rslt=&age_v=&gndr=&intr=&&outc=&spons=&lead=&id=cnty=&state=city=&dist=locln=&sub=&strd_s=&prcd_s=&rfd_e=&sfpd_s=&lupd_s=&lupd_e=&sort=. Accessed 21 Aug 2020

NIH US National Library of Medicine clinical trial database. https://clinicaltrials.gov/ct2/results?cond=Covid19&term=hydroxychloroquine&type=&rslt=&age_v=&gndr=&intr=&&outc=&spons=&lead=&id=cnty=&state=city=&dist=locln=&sub=&strd_s=&prcd_s=&rfd_e=&sfpd_s=&lupd_s=&lupd_e=&sort=. Accessed 21 Aug 2020

NIH US National Library of Medicine clinical trial database. https://clinicaltrials.gov/ct2/results?cond=Covid19&term=hydroxychloroquine&type=&rslt=&age_v=&gndr=&intr=&&outc=&spons=&lead=&id=cnty=&state=city=&dist=locln=&sub=&strd_s=&prcd_s=&rfd_e=&sfpd_s=&lupd_s=&lupd_e=&sort=. Accessed 21 Aug 2020

NIH US National Library of Medicine clinical trial database. https://clinicaltrials.gov/ct2/results?cond=Covid19&term=hydroxychloroquine&type=&rslt=&age_v=&gndr=&intr=&&outc=&spons=&lead=&id=cnty=&state=city=&dist=locln=&sub=&strd_s=&prcd_s=&rfd_e=&sfpd_s=...
identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog 7:e1002331

Pillaiyar T, Meenakshisundaram S, Manickam M (2020) Recent discovery and development of inhibitors targeting coronaviruses. Drug Discov Today 25:668–688

Rinaldo Jr CR (2005) Passive immunization against poliomyelitis: the Hammon gamma globulin field trials, 1951-1953. Am J Public Health 95:790–799

Rolain J-M, Colson P, Raoult D (2007) Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 30:297–308

Santos JR, Curran A, Navarro-Mercade J, Ampuero MF, Pelaez P, Pérez-Alvarez N, Clotet B, Pareides R, Moltó J (2019) Simplification of antiretroviral treatment from darunavir/ritonavir monotherapy to darunavir/cobicistat monotherapy: effectiveness and safety in routine clinical practice. AIDS Res Hum Retroviruses 35:513–518

Savarin A, Di Trani L, Donatelli I, Cauda R, Cassone A (2006) New insights into the antiviral effects of chloroquine. Lancet Infect Dis 6:67–69

Schneider WM, Chevillotte MD, Rice CM (2014) Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol 32:513–545

Schoeman D, Fielding BC (2019) Coronavirus envelope protein: current knowledge. Virol J 16:69

Sheahan TP, Sims AC, Leist SR, Schiffer A, Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO, Spahn JE, Bauer L, Sellers S, Porter D, Feng JY, Cihlar T, Jordan R, Denison MR, Baric RS (2020) Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 11:222

Shih H-I, Wu C-J, Tu Y-F, Chi C-Y (2020) Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines. Biomed J S2319-4170:30085–30085

Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, Zhu H, Zhao W, Han Y, Qin C (2019) From SARS to MERS, thwarting coronaviruses into the spotlight. Viruses 11:piiE59

Soo YO, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KK, Ng MH, Chan P, Cheng G, Sung JJ (2004) Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 10:676–678

Sorrentino and Celularity to initiate emergency allogeneic natural killer (NK) cell therapy development for coronavirus infection. https://seekingalpha.com/pipe/17762358-sorrentino-and-celularity-to-initiate-emergency-allogeneic-naturalkiller-nk-cell-therapy. Accessed 1 Apr 2020

Srinivasan S, Ghosh M, Maity S, Varadarajan R (2016) Broadly neutralizing antibodies for therapy of viral infections. Antit Technol J 6:1–15

Ströher U, DiCaro A, Li Y, Strong JE, Aoki F, Plummer F, Jones SM, Feldmann H (2004) Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-alpha. J Infect Dis 189:1164–1167

Su S, Wong G, Liu Y, Gao GF, Li S, Bi Y (2015) MERS in South Korea and China: a potential outbreak threat? Lancet 385:2349–2350

Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, Moore MJ, Tallarico AS, Olsurine M, Choe H, Anderson LJ, Bellini WJ, Farzan M, Marasco WA (2004) Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci USA 101:2536–2541

ter Meulen J, Bakker AB, van den Brink EN, Weverling GJ, Martina BE, Haagmans BL, Kuiken T, de Kruif J, Preiser W, Spaan W, Gelderblom HR, Goudsmit J, Osterhaus AD (2004) Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 363:2139–2141

Wang Y, Fei D, Vanderlaan M, Song A (2004) Biological activity of a 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem 279:3197–3201

The World Health Organization Home. Coronavirus disease 2019 current case numbers. https://www.who.int/emergencies/diseases/novel-coronavirus-2019 Accessed 21 Aug 2020

The World Health Organization Regional Office for Europe. Health topics. Coronavirus disease (COVID-19) outbreak news. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-a-nounces-covid-19-outbreak-a-pandemic Accessed 18 Apr 2020

https://www.tennesseenews.com/health/article/covid-19-vaccine-tracker-who-says-russian-sputnik-v-yet-to-complete-advanced-trials-updates-of-virus-jabs/636780. Accessed 15 Aug 2020

Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A (2004) An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10:871–875

Uyeki TM (2018) Oseltamivir treatment of influenza in children. Clin Infect Dis 66:1501–1503

van Griensven J, Edwards T, de Lamberlisse X, Semple MG, Gallian P, Baize S, Horby PW, Raoul H, Magassouba N, Antierens A, Lomas C, Faye O, Sall AA, Fransen K, Bayze J, Ravinetto R, Tiberghien P, Claeyss Y, De Crop M, Lynen L, Bah EI, Smith PG, Delamou A, De Wegerheire A, Haba N, Ebola-Tx Consortium (2016) Evaluation of convalescent plasma for Ebola virus disease in Guinea. N. Engl J Med 374:33–42

Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. J Virol 2:69

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China. JAMA. https://doi.org/10.1001/jama.2020.2467

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269–271

Wang Y, Fei D, Vanderlaan M, Song A (2004) Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7:335–345

Wang Y, Jiang Y, Zhao C, He W (2019) Use of carrimycin in Mycobacterium tuberculosis infection resistance. China. US20190001160A1, 1 Mar 2019

Wang Z, Chen X, Lu Y, Chen F, Zhang W (2020) Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends 14:64–8

Wang Z, Han W (2018) Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res 6:4

Wenzel RP, Edmond MB (2003) Managing SARS amidst uncertainty. N. Engl J Med 348:1947–1948

Wong JEL, Leo YS, Tan CC (2020) COVID-19 in Singapore-current experience: critical global issues that require attention and action. JAMA. https://doi.org/10.1001/jama.2020.2467

Wong SK, Li W, Moore MJ, Choe H, Farzan M (2004) A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem 279:3197–3201
